Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.10 -1.32% 7.45 7.30 7.60 7.55 7.45 7.55 61,393 09:30:26
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -3.1 -2.7 - 10

Evgen Pharma Share Discussion Threads

Showing 1726 to 1750 of 1850 messages
Chat Pages: 74  73  72  71  70  69  68  67  66  65  64  63  Older
DateSubjectAuthorDiscuss
31/10/2019
19:47
I have never called a top correctly before, so it would be a first! As long as the results are satisfactory though, it can settle wherever it wants pre-results. That said, I did toy with the idea of buying some more of these to trade last week, but held off doing so unfortunately. Had a good day on paper with this and two other small cap stocks I am holding, so more treats than tricks....
lovewinshatelosses
31/10/2019
19:22
Ps LWHL...maybe we will see your climb to 18p pre-news
pennyfalls
31/10/2019
19:21
Hi Waterloo, imo I don’t think it’ll be an institutional investor at this late stage, and the volumes are still relatively low. Institutions usually don’t wait until the death to get in and I think would have been building earlier (as a couple of big investors did in the 15p fundraiser) Reckon, today’s buys have been PIs with this in their diaries and mid Q4 is upon us, or someone has seen a few smiles in the office ;o)
pennyfalls
31/10/2019
17:06
Mainly 50k trades or higher makes me think it's an II building a position?
waterloo01
31/10/2019
17:04
A very gratifying day and hopefully more to come soon.
lovewinshatelosses
31/10/2019
14:55
Yes, I agree that slippage of timelines can occur. Hence, great if we receive results in November. Also fine if in December.... but wow... the share price move today is behaving as if the results will be out very soon. Looking forward to the results!
diamondstar1
31/10/2019
14:24
Diamond I appreciate what you are saying but as usual delays occur!You remember a few months ago they said results by end of 3rd quarter or start of 4th.Then revised later to 4th quarter.I would not be surprised if we have to wait to December
dave444
31/10/2019
12:01
Hi Dave, My projections are for an early Nov - mid November release of study results. This is based on the following information. On 28 Aug 2019, Evgen announced that Last Patient, Last Study Visit (LPLSV) had already taken place. This means that all data in the study would have been collected. Then there is a process of gathering all the data, putting it into tables and listings, raising queries on the data. Finally, this process ends with the Database Lock (DBL) whereby no further changes are allowed. This process usually takes 4-6 weeks after LPLSV. Hence, that takes us mid-October (assuming 6 weeks for DBL). From DBL, Evgen and their KOLs would be busy evaluating the study data (i.e. the 3 Primary Outcome Measures & 5 Secondary Outcome Measures) and getting ready for the press release and study result presentations. This process of evaluating the data should take anywhere between 2-4 weeks. Therefore, my estimate indicates that the results should be out anytime from Nov 1st till mid-Nov. Of course, there could be slight delays, for example, if there are additional data queries or analysis of the study results are difficult, which may delay disclosure by ~2 weeks. However, you must remember that the study has been going on for several years, and the study has only 89 evaluable patients. Hence, when Evgen announced on 28 Aug 2019 that LPLSV had taken place - most of the study data would already have been collected on majority of patients, and it was simply gathering the last bits of data from the last few patients. This would likely minimise data queries at the end.
diamondstar1
31/10/2019
11:59
lol. Rode RENE and sold at 200% up and ditto SLN (still hold a few). Timing, both buying and selling, is rather key as we both know.
waterloo01
31/10/2019
11:53
Good timing waterloo. You are the guru!
nobbygnome
31/10/2019
10:48
I assume results will be known in December
dave444
31/10/2019
09:48
Bar is very low here. I think they will make it.
hsm12
31/10/2019
07:44
Nobby, no have very little direct knowledge. Been on my radar and near a read-out, so just a small punt.
waterloo01
30/10/2019
19:26
>> waterloo Interesting to see you have bought in here. I have a small position but am reticent to buy any more. I don't really have any specific reason like my scientific analysis over at IMM but I guess it's just gut feeling. Are you confident of a good result? I can see much better short term opportunities elsewhere such as STX and SBTX.
nobbygnome
30/10/2019
19:14
Took a 1st small position today. Some very large trades (not mine). Always value diamondstar1 and Timbo's input. Knowledgeable chaps.
waterloo01
30/10/2019
19:12
Thanks diamondstar.
lovewinshatelosses
30/10/2019
18:35
Timbo - the 40% figure I quoted comes from Medscape, and is based on hospitalised SAH patients. The mortality would be even higher considering the 20% who pass away before reaching hospital. Shows you how devastating this disease is. LWHL - the trial would be of similar duration for the patient. However, the patient numbers would increase. For the pivotal Ph3 Nimodipine trial, N = 554. This would mean that you will need more sites and countries running the study. How fast the Ph3 study is run will depend on how much money you have, as you could set up more sites/countries. Obviously, a licensing deal with a Pharma partner would be ideal.
diamondstar1
30/10/2019
17:38
Does anyone know approximately how long phase 3 would likely take, in the event all goes well here and such things become applicable - or it that a piece of string question?
lovewinshatelosses
30/10/2019
16:54
The last few posts remind me of something SF mentioned at one of the investor meetings a few months ago i.e. don't confuse the overall mortality (30-40%) for SAH with mortality in hospitalised patients (which is a significantly lower figure), because around 20% of patients with SAH never make it (alive) to hospital for treatment.
timbo003
30/10/2019
16:15
Good post Nelson. Evaluable subjects - this is also known from a statistical perspective as the Per Protocol Set (PPS). These are patients who have 1)Completed a minimum predefined observational period 2)Have measurements for the Primary Outcome 3)Have not met criteria for Major Protocol Violations. Usually, you get a few patients who do not make it to the PPS. Hence, this could explain the potential discrepancy between 9.5% and 16%. Hence, mortality could be closer to 10% (as per figure at 71% enrollment) or slightly higher, and you may also have a few % of patients excluded from the final analysis (example, due to major protocol violations or incomplete data).
diamondstar1
30/10/2019
15:46
That's interesting figures, I've also read 107 patients recruited with 89 being evaluable. Which I took as 16% mortality rate.
90005nelson
30/10/2019
14:55
That's great information you've posted L0ngterm! Overall mortality with 71% patients - at 9.5% is VERY low, compared to overall mortality rates for SAH in general, near 30-40%. Hence, it looks to me like more healthy patients were enrolled (i.e. patients with reduced conscious state/coma or severe hemiplegia excluded). This is promising - to maximise potential effects on Rankin Score, which is a Secondary Outcome Measure.
diamondstar1
30/10/2019
14:44
Some figures from March 2019 on the trial. Link below. "64 (71% of the target) patients have been enrolled. 35 patients have completed the study. Statistical analysis of the TCD data will be performed at the end of the trial. The mortality is at 9.5% (6). DSMB have met twice since the start of the trial and there have been no safety concerns. Conclusions The trial is recruiting on the planned trajectory and at this rate we are projected to complete the trial by the end of the year."https://www.google.co.uk/amp/s/www.researchgate.net/publication/331102933_WM1-2_SFX-01_after_subarachnoid_haemorrhage_protocol_of_a_multi-centre_phase_II_double-blinded_randomised_controlled_trial/amp
l0ngterm
30/10/2019
14:02
I anticipate that the study results will be out over the next 2 weeks. Here are my predictions of the study results, for the 3 Primary Outcome Measures:- 1) Adverse Event Evaluation (safety of SFX-01 vs. placebo) - this is really a no brainer for me - because previous public disclosures by Evgen on the DSMB (Data Safety Monitoring Board ) findings have already indicated that the drug is very safe and well tolerated vs. placebo. CONCLUSION - SFX-01 very safe in SAH patients 2) Maximum CSF concentration - previous animal studies have shown that SFX-01 crosses the blood brain barrier (BBB). SFX-01 being a small molecule, should have no problems crossing BBB. CONCLUSION - DRUG WILL BE FOUND IN CSF, PASS! 3) No of patients with reductions in middle cerebral artery (MCA) peak flow velocity. Previous animal studies have shown that SFX-01 alleviates cerebral artery vasospasm secondary to oxyhaemoglobin formation. Note - only 30-40% of patients will have significant vasospasm after SAH - but I would expect SFX-01 to have positive effects in these patients. CONCLUSION - LIKELY SOME POSITIVE EFFECT WILL BE SEEN, MAINLY IN SUBSET OF PATIENTS WITH CEREBRAL ARTERY VASOSPASM. The results will be very very interesting if they find that SFX-01 reduces mortality in SAH patients vs. placebo. Note that this reduction in mortality has been seen in several animal studies with NRF2 activators:- ref: Neuroprotective Role of the Nrf2 Pathway in Subarachnoid Haemorrhage and Its Therapeutic Potential (Zolnourian et al, 2019). A reduction in mortality, if seen, could impact the Secondary Outcome Measure of the study - namely the Rankin Score - if more patients actually survive on SFX-01 vs. placebo. Paradoxically, those who survive on SFX-01 could be left with more significant neurological deficit. Hence, SFX-01 may have the potential to help SAH patients survive, who might have otherwise perished if they did not receive SFX-01. Will be interesting to see overall effect on Rankin Score. Interesting times ahead - I'm looking forward to the results! Primary Outcome Measures - likely to be very good, but secondary outcome measures may be interesting, especially if SFX-01 impacts mortality. Overall, I'd expect this study to give the green light for the next phase i.e. Ph3.
diamondstar1
25/10/2019
17:25
Results anytime from next week.
90005nelson
Chat Pages: 74  73  72  71  70  69  68  67  66  65  64  63  Older
Your Recent History
LSE
EVG
Evgen Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191208 03:46:30